July 10th, 2025
Vilnius, Lithuania and Willowbrook (IL), US – July 8th, 2025 – Farma Mondo UAB, a subsidiary in Baltics of the FarmaMondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, and Pharmazz Inc. (“Pharmazz”) an innovative biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine, announce the signing of an exclusive partnership for the distribution of Tycamzzi™ in Baltics.
Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented: We are excited to partner with Pharmazz for its innovative therapy and bringing advanced care to patients in Baltic countries. I thank Pharmazz leadership and Dr. Anil Gulati for their trust in FarmaMondo Group.
Anil Gulati, CEO of Pharmazz, said, “Tycamzzi™ represents a groundbreaking approach to stroke treatment by preventing neuronal cell death and stimulating dormant regenerative cells to repair damaged brain tissue. Clinical studies have demonstrated statistically significant improvements in neurological outcomes, underscoring its therapeutic potential. We look forward to leveraging Farma Mondo’s strong presence in the Baltics to help bring this innovative therapy to stroke patients.”
About Tycamzzi™
Tycamzzi™ (Sovateltide), a highly selective endothelin-B receptor agonist and synthetic analog of endothelin-1, is a neural progenitor cell therapeutic agent for the treatment of acute cerebral ischemic stroke (ACIS), hypoxic-ischemic encephalopathy (HIE), spinal cord injuries, and Alzheimer’s disease. In May 2023, sovateltide was approved in India for the treatment of cerebral ischemic stroke within 24 h of stroke onset.
About Farma Mondo Group
Farma Mondo is a fast-growing Swiss group committed to providing healthcare professionals and the patients they care for with commercial access to innovative medicines.
Farma Mondo offers biopharmaceutical innovators a high-value, end-to-end commercialization partnership in emerging markets, based on our unique expertise and geographic footprint, and aimed at providing patients with access to innovative specialty medicines.
FarmaMondo serves as a one-stop commercial partner, providing access to key emerging markets through a single Swiss-based relationship and 14 operational locations.
For more details, please visit https://farmamondo.com/
About Pharmazz, Inc.
Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, a promising drug pipeline, and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA, focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine.
For more details, please visit www.pharmazz.com.
